Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

266
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
266
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

101
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
101

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Divergent roles of SPOP and CHD1 in ACSL4 regulation reveal context-dependent vulnerabilities for targeting ferroptosis.

Nature communications·2026
Same author

Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers.

iScience·2026
Same author

Implementing intervention mapping to tailor the evidence-based PREDIMED intervention for medically underserved prostate cancer patients.

Translational behavioral medicine·2026
Same author

Improve the Efficacy of B7-H3-Targeting Antibody-Drug Conjugate DS-7300a in TP53-deficient Tumors by Inducing Ferroptosis.

bioRxiv : the preprint server for biology·2026
Same author

Globalization of clinical trials: participation, development and future directions.

Current opinion in urology·2026
Same author

A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture.

Cancer discovery·2026
Same journal

Implications of Alpha-gal Syndrome in Urologic Management.

Urology·2026
Same journal

"Editorial Comment on "Vaginal Estrogen Prescription is Associated with Reduced Rates of Serious Adverse Outcomes in Women of All Age Groups With Recurrent Urinary Tract Infection: An Epic Cosmos Database Analysis".

Urology·2026
Same journal

The True Oral History of Buccal Mucosal Grafts for Male Urethral Stricture Repair.

Urology·2026
Same journal

Preventing Postpartum Pelvic Floor Dysfunction: Clinical Evidence and Policy Gaps in U.S. Coverage of Pelvic Floor Muscle Therapy.

Urology·2026
Same journal

Editorial Comment on "Through the Eyes of the Applicant: A Qualitative Study of the Urology Residency Match".

Urology·2026
Same journal

Editorial Comment on "A Histopathologic Assessment of Prostate Ductal Anatomy in Relation to Micro-Ultrasound".

Urology·2026
See all related articles

Related Experiment Video

Updated: May 13, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

12.9K

GLP-1 Agonist Use Among Men With Localized Prostate Cancer: A Narrative Review and Rationale for Prospective Clinical

Andrew Fang1, Daniel E Frigo1, Andrew Hahn1

  • 1MD Anderson Cancer Center, The University of Texas, Houston, TX.

Urology
|May 10, 2025
PubMed
Summary
This summary is machine-generated.

Glucagon-like peptide 1 (GLP-1) receptor agonists show promise in reducing prostate cancer risk. Further research is needed to understand their effects on tumor biology and potential clinical applications.

More Related Videos

Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

7.6K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.1K

Related Experiment Videos

Last Updated: May 13, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

12.9K
Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

7.6K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.1K

Area of Science:

  • Endocrinology and Oncology
  • Metabolic Disease Research

Background:

  • Glucagon-like peptide 1 (GLP-1) receptor agonists are established obesity treatments.
  • Epidemiological studies suggest a potential inverse relationship between GLP-1 receptor agonist use and prostate cancer incidence.

Purpose of the Study:

  • To investigate the impact of lifestyle interventions on men with prostate cancer.
  • To clarify the association between lifestyle interventions and prostate cancer risk.
  • To explore the mechanistic effects of GLP-1 receptor agonists on prostate cancer biology.

Main Methods:

  • Review of epidemiological data on GLP-1 receptor agonist use and prostate cancer.
  • Analysis of changes in prostate cancer patients undergoing lifestyle interventions.
  • Exploration of molecular mechanisms linking GLP-1 action to tumor biology.

Main Results:

  • The study aims to define changes in prostate cancer patients post-lifestyle intervention.
  • It will illuminate the current relationship between these interventions and prostate cancer risk.
  • It will explore potential mechanisms of action on tumor biology.

Conclusions:

  • GLP-1 receptor agonists may offer a novel therapeutic avenue for prostate cancer management.
  • Further clinical trials are warranted to evaluate the efficacy of GLP-1 receptor agonists in men with prostate cancer.